Back to search results

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

This study is looking into whether genetic factors play a role in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), a condition with pain in the pelvic area, urinary issues, or sexual dysfunction. Researchers believe some types of CP/CPPS might be inherited. You may be able to join if you have CP/CPPS, Interstitial Cystitis (IC), Bladder Pain Syndrome (BPS), or Bladder Fasciculation Syndrome (BFS) with symptoms for at least 3 months in the past 6 months. Family members of someone with CP/CPPS can also join, even if they don't have symptoms. The study aims to find specific genetic changes linked to these conditions. This is an observational study, meaning no new treatments are being tested.

Study design
This is an observational study planning to enroll 500 participants. It is not testing any specific interventions or drugs.
What's involved
You would provide a blood or saliva sample, a urine sample, and answer questionnaires. If you are an affected participant, you may also be asked to provide a bladder sample from a clinical biopsy.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment until the completion of genetic analysis, which could be up to 22 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00499317

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Recruiting
Not specifiedAll AgesObservational
Boston Children's Hospital
~500 participants
Updated 2026-06-11 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Participants With Candidate Disease-Causing Genetic Variant(s) Associated With CP/CPPS or IC/BPS
Measured over From enrollment until completion of genetic analysis for the participant or family, up to 22 years.

Conditions

Chronic Prostatitis (CP)
Chronic Pelvic Pain Syndrome (CPPS)
Painful Bladder Syndrome (PBS)
Benign Frequency Syndrome (BFS)
Interstitial Cystitis

Explore related trials

Benign Frequency SyndromeChronic primary bladder pain syndromeChronic primary pelvic pain syndromeChronic ProstatitisInterstitial Cystitis

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Catherine Brownstein, PhD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital

Who to contact

Elicia Estrella, MS, LCGC
[email protected]
617-919-4552
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have symptoms for at least 3 months within the preceding 6 months:
Pain in the pelvic area
Urinary frequency and/or
Urinary urgency and/or
Sexual dysfunction (erectile dysfunction)
Have CP/CPPS, Interstitial Cystitis (IC), Bladder Pain Syndrome BPS, or Bladder Fasciculation Syndrome (BFS)
Be willing to provide a blood/saliva, bladder tissue (from previous biopsy) and urine sample
Agree to complete several brief questionnaires
Family member of someone with CP/CPPS, BPS, IC or BFS
Live in the USA or Canada

Exclusion

Major structural/anatomical urinary tract abnormalities
Underlying inborn or congenital conditions which affect the urinary tract
Surgery/chemotherapy in the pelvic area
Bacterial cause to CP/CPPS or recurrent Urinary tract infections (UTI)
Traumatic cause to CP/CPPS

What this trial measures

  • Participants With Candidate Disease-Causing Genetic Variant(s) Associated With CP/CPPS or IC/BPSFrom enrollment until completion of genetic analysis for the participant or family, up to 22 years.

    DNA from blood/saliva and, when available, bladder or skin tissue will be analyzed using linkage analysis, whole exome/genome sequencing, and candidate gene approaches to identify candidate disease-causing variants associated with CP/CPPS, IC/BPS, PBS, or BFS. The measure will be summarized as the number of participants with candidate disease-causing variant(s), and when applicable, co-segregation of variants with affected status or symptoms.